Novartis AG NOVN.SW
Novartis AG statistics & valuation
Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($62.49); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
Novartis AG trades at about 17.3× earnings — near its 10-year norm (10-year range 12.6×–29.6×, median 16.3×).
Shaded band = 10-year range (12.6×–29.6×); dot = today's 17.3×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Gross margin | 75.8% | 75.2% | 73.3% | 73.4% |
| Operating margin | 31.1% | 28.1% | 20.9% | 18.3% |
| Net margin | 24.7% | 23.1% | 31.8% | 16.0% |
| FCF margin | 26.9% | 26.7% | 25.1% | 27.6% |
| Return on assets | 12.6% | 11.7% | 14.9% | 5.9% |
| Return on equity | 30.3% | 27.1% | 31.8% | 11.7% |
| Debt / equity | 0.61× | 0.49× | 0.40× | 0.34× |
| Current ratio | 1.12 | 1.04 | 1.16 | 1.29 |
Computed from company filings · CH · as of 2025-12-31. Figures in USD. Facts plus Stocktoria's own computed scores — not investment advice.